What is the recommended acute management for a COPD exacerbation?

Acute Management of COPD Exacerbation

Immediately initiate combined short-acting bronchodilators (salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg via nebulizer every 4–6 hours), oral prednisone 30–40 mg daily for exactly 5 days, and antibiotics for 5–7 days when sputum purulence is present with either increased dyspnea or sputum volume; use non-invasive ventilation as first-line therapy for acute hypercapnic respiratory failure. 1

Immediate Bronchodilator Therapy

• Administer combined nebulized salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg every 4–6 hours during the acute phase, as this combination provides superior bronchodilation lasting 4–6 hours compared with either agent alone. 1

• Nebulizers are preferred over metered-dose inhalers in hospitalized or severely dyspneic patients because they eliminate the need for coordinating 20+ inhalations and are easier to use when patients are acutely ill. 1

• Power nebulizers with compressed air (not oxygen) when hypercapnia or respiratory acidosis is present, delivering supplemental oxygen separately via nasal cannula at 1–2 L/min. 1

• Continue scheduled nebulized bronchodilators every 4–6 hours until clinical improvement occurs, typically within 24–48 hours, then transition to metered-dose inhalers with spacer. 1

• Avoid intravenous methylxanthines (theophylline/aminophylline) entirely, as they increase adverse effects without providing clinical benefit. 1, 2

Systemic Corticosteroid Protocol

• Give oral prednisone 30–40 mg once daily for exactly 5 days starting immediately upon presentation; this short course is as effective as a 14-day regimen while reducing cumulative steroid exposure by more than 50%. 1, 2

• Oral administration is equally effective to intravenous and should be the default route unless the patient cannot tolerate oral intake. 1

• This 5-day regimen improves lung function and oxygenation, shortens recovery time and hospital stay, reduces treatment failure by over 50%, and lowers the risk of rehospitalization within the first 30 days. 1, 2

• Do not extend systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists, as longer courses increase adverse effects without added benefit. 1

Antibiotic Therapy

• Prescribe antibiotics for 5–7 days when sputum purulence is present together with either increased dyspnea OR increased sputum volume (two of three cardinal symptoms, with purulence required). 1

• Antibiotic therapy reduces short-term mortality by approximately 77%, treatment failure by 53%, and sputum purulence by 44%. 1, 2

• First-line oral agents include amoxicillin-clavulanate 875/125 mg twice daily, doxycycline 100 mg twice daily, or azithromycin (500 mg day 1, then 250 mg daily for 4 days), selected according to local resistance patterns. 1

• Target the most common bacterial pathogens: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. 1

Oxygen Management

• Target oxygen saturation of 88–92% using controlled-delivery devices (Venturi mask 24–28% FiO₂ or nasal cannula 1–2 L/min) to correct life-threatening hypoxemia while minimizing CO₂ retention. 1

• Obtain an arterial blood gas within 60 minutes of initiating oxygen to identify hypercapnia (PaCO₂ > 45 mmHg) or acidosis (pH < 7.35). 1

• If the initial ABG shows normal pH and PaCO₂, the saturation target may be increased to 94–98% only if the patient has no prior history of hypercapnic failure requiring NIV and their usual stable saturation is ≥94%. 1

• High-flow oxygen (>28% FiO₂ or >4 L/min) delivered without concurrent blood-gas monitoring worsens hypercapnic respiratory failure and increases mortality by approximately 78%. 1

Non-Invasive Ventilation (NIV)

• Initiate NIV immediately as first-line therapy when acute hypercapnic respiratory failure (PaCO₂ > 45 mmHg) with acidosis (pH < 7.35) persists for more than 30 minutes after standard medical treatment. 1, 2

• NIV improves gas exchange, reduces work of breathing, decreases intubation rates by approximately 50%, shortens hospital stay, and improves survival; success rates in appropriately selected patients are 80–85%. 1, 2

• Transfer to ICU if pH remains <7.26 despite NIV. 1

• Contraindications to NIV include altered mental status with inability to protect the airway, large-volume secretions, hemodynamic instability, or recent facial/upper-airway surgery. 1

Hospitalization Criteria

Admit or evaluate in the emergency department if any of the following are present: 1

• Marked increase in dyspnea unresponsive to outpatient therapy
• Respiratory rate >30 breaths/min
• Inability to eat or sleep because of respiratory symptoms
• New or worsening hypoxemia (SpO₂ <90% on room air)
• New or worsening hypercapnia (PaCO₂ >45 mmHg)
• Altered mental status or loss of alertness
• Persistent rhonchi after initial treatment requiring continued nebulization
• High-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes, renal or liver failure)
• Inability to care for self at home

Discharge Planning

• Schedule pulmonary rehabilitation within 3 weeks after discharge to reduce readmissions and improve quality of life; initiating rehabilitation during hospitalization is associated with increased mortality. 1

• Optimize long-acting bronchodilator therapy (LAMA, LABA, or combinations) before discharge and do not step down from triple therapy (LAMA + LABA + ICS) during or immediately after an exacerbation, as inhaled corticosteroid withdrawal raises the risk of recurrent exacerbations. 1

• Verify proper inhaler technique at discharge. 1

• Provide smoking cessation counseling with nicotine replacement therapy and behavioral support for current smokers. 1

• Schedule follow-up within 3–7 days to assess treatment response. 1

Common Pitfalls to Avoid

• Never power nebulizers with oxygen in hypercapnic patients; use compressed air and provide supplemental oxygen via a separate nasal cannula. 1

• Never delay NIV when criteria for acute hypercapnic respiratory failure are met (pH <7.35, PaCO₂ >45 mmHg persisting >30 minutes). 1

• Never use methylxanthines (theophylline/aminophylline) in acute exacerbations—they add toxicity without benefit. 1, 2

• Never continue systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists. 1

• Never administer high-flow oxygen without arterial blood-gas monitoring, as this can worsen hypercapnic respiratory failure and increase mortality. 1